Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing
Mariano A. Garcia-Blanco
Mariano A. Garcia-Blanco
View: Text | PDF
Perspective Series

Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing

  • Text
  • PDF
Abstract

In the human genome, the majority of protein-encoding genes are interrupted by introns, which are removed from primary transcripts by a macromolecular enzyme known as the spliceosome. Spliceosomes can constitutively remove all the introns in a primary transcript to yield a fully spliced mRNA or alternatively splice primary transcripts leading to the production of many different mRNAs from one gene. This review examines how spliceosomes can recombine two primary transcripts in trans to reprogram messenger RNAs.

Authors

Mariano A. Garcia-Blanco

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
The structure of human genes and primary transcripts. A schematic of a g...
The structure of human genes and primary transcripts. A schematic of a gene (DNA), its primary transcript (pre-mRNA), and the mature mRNA product. The gene in this schematic spans four exons (boxes 1 through 4) and three introns. Genomic landmarks are indicated for the middle intron: the 5′ splice site (5′ ss), the branchpoint (BP) adenosine, the polypyrimidine tract (Py), and the 3′ splice site (3′ ss). The structure of the pre-mRNA, which is synthesized by RNA polymerase II, is shown. The 5′ end of the pre-mRNA is determined by transcription initiation and modified by a cap structure (27). The 3′ end is created and modified by cleavage and polyadenylation (poly A). Introns are removed in pre-mRNA splicing to yield an mRNA. On average, introns are longer than 3,000 nucleotides. The 5′ and 3′ terminal exons (1 and 4) average 300 nucleotides in length; internal exons (2 and 3) average 145 nucleotides in length (14, 15).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts